CA2817519C - Bin1 expression as a marker of skeletal muscle mass and neurological conditions - Google Patents

Bin1 expression as a marker of skeletal muscle mass and neurological conditions Download PDF

Info

Publication number
CA2817519C
CA2817519C CA2817519A CA2817519A CA2817519C CA 2817519 C CA2817519 C CA 2817519C CA 2817519 A CA2817519 A CA 2817519A CA 2817519 A CA2817519 A CA 2817519A CA 2817519 C CA2817519 C CA 2817519C
Authority
CA
Canada
Prior art keywords
seq
bin1
antibody
human
skeletal muscle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2817519A
Other languages
English (en)
French (fr)
Other versions
CA2817519A1 (en
Inventor
Darryl Steven Shaw
Neil Gavin Shaw
Original Assignee
SARCOTEIN DIAGNOSTICS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SARCOTEIN DIAGNOSTICS LLC filed Critical SARCOTEIN DIAGNOSTICS LLC
Publication of CA2817519A1 publication Critical patent/CA2817519A1/en
Application granted granted Critical
Publication of CA2817519C publication Critical patent/CA2817519C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2817519A 2010-11-09 2011-11-07 Bin1 expression as a marker of skeletal muscle mass and neurological conditions Active CA2817519C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41168310P 2010-11-09 2010-11-09
US61/411,683 2010-11-09
PCT/US2011/059574 WO2012087437A2 (en) 2010-11-09 2011-11-07 Bin1 expression as a marker of skeletal muscle mass and neurological conditions

Publications (2)

Publication Number Publication Date
CA2817519A1 CA2817519A1 (en) 2012-06-28
CA2817519C true CA2817519C (en) 2020-01-14

Family

ID=46314702

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2817519A Active CA2817519C (en) 2010-11-09 2011-11-07 Bin1 expression as a marker of skeletal muscle mass and neurological conditions

Country Status (6)

Country Link
US (1) US9891232B2 (https=)
EP (1) EP2638403B1 (https=)
JP (1) JP5866126B2 (https=)
AU (2) AU2011345312A1 (https=)
CA (1) CA2817519C (https=)
WO (1) WO2012087437A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120094300A1 (en) 2009-04-24 2012-04-19 Robin Shaw Bin1 as a Prognostic Marker in Cardiovascular Disease
JP5890840B2 (ja) * 2010-10-20 2016-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓健康状態のマーカーとしての体液ｂｉｎ１
US9846159B2 (en) 2011-09-30 2017-12-19 Sarcotein Diagnostics, Llc BIN1 expression as a marker of cancer
JP6742330B2 (ja) 2015-03-02 2020-08-19 サーコーティン ダイアグノスティックス エルエルシー 心臓障害のマーカーとしての１３＋／１７＋ｂｉｎ１発現
JP6539511B2 (ja) * 2015-06-17 2019-07-03 花王株式会社 運動機能の判定用マーカー
JP6886241B2 (ja) * 2016-01-07 2021-06-16 味の素株式会社 骨格筋面積の評価方法
CA3022515A1 (en) * 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
CN112770723B (zh) * 2018-07-25 2024-08-02 阿克罗斯生物科学公司 Cldn 18.2特异性单克隆抗体及其使用方法
CA3115077A1 (en) * 2018-10-09 2020-04-16 Ibex Biosciences, Llc Antibodies directed to filamin-a and therapeutic uses thereof
US20240026034A1 (en) * 2020-12-15 2024-01-25 Arizona Board Of Regents On Behalf Of Arizona State University Antibodies specific for qsox1 and methods of using the same
CN112794900B (zh) * 2020-12-31 2022-10-25 中南大学湘雅二医院 cBIN1抗体及其应用
CN112778414B (zh) * 2020-12-31 2022-04-15 中南大学湘雅二医院 cBIN1抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048702A (en) * 1995-05-05 2000-04-11 The Wistar Institute Of Anatomy And Biology Murine and human box-dependent myc-interacting protein (Bin1) and uses therefor
CA2378982A1 (en) * 1999-07-07 2001-01-18 Regeneron Pharmaceuticals, Inc. Methods of inhibiting muscle atrophy
US6831063B1 (en) * 1999-08-31 2004-12-14 The Wistar Institute Of Anatomy And Biology Bridging Integrator-2(Bin2) nucleic acid molecules and proteins and uses therefor
WO2005037230A2 (en) * 2003-10-14 2005-04-28 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating heart failure
CA2578680C (en) 2004-04-15 2011-06-14 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
WO2006009629A2 (en) * 2004-06-10 2006-01-26 New York University Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same
WO2008008846A2 (en) * 2006-07-11 2008-01-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Differential expression of molecules associated with intra-cerebral hemorrhage
US20120094300A1 (en) * 2009-04-24 2012-04-19 Robin Shaw Bin1 as a Prognostic Marker in Cardiovascular Disease
JP5890840B2 (ja) * 2010-10-20 2016-03-22 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓健康状態のマーカーとしての体液ｂｉｎ１

Also Published As

Publication number Publication date
EP2638403A4 (en) 2014-05-07
JP2014500960A (ja) 2014-01-16
WO2012087437A3 (en) 2012-08-16
JP5866126B2 (ja) 2016-02-17
EP2638403A2 (en) 2013-09-18
US20130324432A1 (en) 2013-12-05
WO2012087437A2 (en) 2012-06-28
AU2011345312A1 (en) 2013-06-20
AU2017201661B2 (en) 2019-01-17
US9891232B2 (en) 2018-02-13
EP2638403B1 (en) 2017-03-22
CA2817519A1 (en) 2012-06-28
AU2017201661A1 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
AU2017201661B2 (en) BIN1 expression as a marker of skeletal muscle mass and neurological conditions
CN110720041B (zh) 用心肌肌钙蛋白i和早期生物标记物帮助诊断和评价人受试者中轻度创伤性脑损伤的方法
JP7437303B2 (ja) 外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法
EP2300624B1 (en) Biomarkers for painful intervertebral discs and methods of use thereof
US7709215B2 (en) Method for diagnosing and treating acute joint injury
JP2019007759A (ja) 老化度を評価する方法及び老化度の評価用キット
WO2008079406A2 (en) Gene expression markers for inflammatory bowel disease
KR101289134B1 (ko) 유전성 샤르코-마리-투스 말초신경병증의 cmt4b3 아형에 대한 원인 유전자로서의 sbf1(mtmr5) 돌연변이 유전자 및 이를 이용한 상기 질병의 진단방법 및 진단용 조성물
JP2013039111A (ja) スプライシングバリアント
JP2007524408A (ja) 精神障害の診断および処置
KR101849684B1 (ko) 샤르코-마리-투스병 제2형의 원인 유전자로서 ｍｏｒｃ２ 및 이를 이용한 상기 질병의 진단방법
EP2128272A1 (en) Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor
US6680172B1 (en) Treatments and markers for cancers of the central nervous system
EP3133400B1 (en) Use of ak6 and gpx5 male fertility related proteins or combination thereof
CN110499366B (zh) Pi15作为骨关节炎标志物的应用
KR102202120B1 (ko) 알츠하이머 질환의 진단 또는 치료를 위한 Ｕｂｅ２ｈ의 용도
CN109295207A (zh) Agap9在制备诊断骨关节炎的产品中的应用
US9638699B2 (en) Biomarkers of oxidative stress
WO2026052672A1 (en) Comp cleavage peptide and its use in diagnosis of osteoarthritis
WO2007080664A1 (ja) 中枢神経系原発悪性リンパ腫マーカーおよびその用途
KR101849685B1 (ko) 샤르코-마리-투스병 제1형의 원인 유전자로서 ｐｍｐ２２ 및 이를 이용한 상기 질병의 진단방법
KR101289114B1 (ko) 조기발병하는 상염색체 열성 축삭형 샤르코-마리-투스병의 원인 유전자로서 hadhb 돌연변이 유전자, 이를 이용한 상기 질병의 진단방법 및 진단용 조성물
WO2010055525A1 (en) Method for predicting a patient's responsiveness to anti-folate therapy
WO2008150964A1 (en) Methods and kits for diagnosing and treating acute joint injury
AU2011239262A1 (en) Osteoarthritis biomarkers and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161013

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241104

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251023

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251023